Key facts
- Kripthonite Therapeutics’s last known valuation is $52.0M (Jun 2025).
- It has raised $8.5M; the latest was Seed Round ($8.5M) in Jun 2025.
- Notable investors include InnoFounder, Aarhus University, Marigold Investment Management.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Kripthonite Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Kripthonite Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kripthonite Therapeutics
Developer of hypoxia-targeting macrocycle therapeutic candidates designed for the treatment of solid tumors. The company utilizes a novel therapeutic platform to develop compounds that selectively target and eliminate hypoxic cancer cells by disrupting their unique energy metabolism and inducing rapid cell death, enabling oncology patients with treatment-resistant, low-oxygen tumors to experience enhanced therapeutic synergy with existing radiation or chemotherapy protocols and improved overall clinical outcomes.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2023
- Employees
- 3
- Website
- kripthonite.com/
- Ownership
- Privately Held (backing)
Kripthonite Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kripthonite Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kripthonite Therapeutics in its N-PORT filings yet. We sweep new filings monthly.